Trump announces trade deal with EU following months of negotiations
Thermo Fisher Scientific Inc. (NYSE:TMO), a $195 billion market cap company with a "Good" InvestingPro Financial Health rating, saw its Executive Vice President Michael D. Shafer recently sell a significant portion of his holdings in the company. According to a recent SEC filing, Shafer sold 1,780 shares of common stock on March 3, 2025, at an average price of $530.92 per share, totaling approximately $945,037. This transaction was executed under a pre-established Rule 10b5-1 trading plan. The stock, which currently trades at a P/E ratio of 31.2x, is near its 52-week low of $493.30.
In addition to the sale, Shafer reported several transactions on February 28, 2025, involving the disposition of shares to cover tax obligations. These transactions involved the disposal of a total of 990.444 shares at a price of $528.96 each, amounting to $523,905.
Following these transactions, Shafer’s direct ownership in Thermo Fisher now stands at 19,279.0236 shares. The adjustments in his holdings reflect both planned sales and performance-based stock unit awards adjustments.
In other recent news, Solventum has announced the sale of its Purification & Filtration business to Thermo Fisher Scientific for $4.1 billion. This transaction, expected to be neutral to Solventum’s earnings per share in 2025, is anticipated to generate approximately $3.4 billion in net proceeds, which the company plans to use primarily for debt reduction. The sale aligns with Solventum’s strategic transformation plan to enhance focus and improve financial metrics. Thermo Fisher, which will integrate this business into its Life Sciences Solutions segment, expects the acquisition to be completed by the end of 2025, pending regulatory approval. Meanwhile, Trian Fund Management, an activist investor with a 5% stake in Solventum, has been advocating for further business separations to concentrate on the company’s medical and surgical unit. Trian believes these actions will address high costs impacting Solventum’s profits. Additionally, Thermo Fisher has made strategic moves of its own, including appointing Karen S. Lynch to its Board of Directors and announcing a 10% increase in its quarterly cash dividend to $0.43 per share. These developments reflect ongoing efforts by both companies to strengthen their financial positions and strategic directions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.